<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168154">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883999</url>
  </required_header>
  <id_info>
    <org_study_id>IBE 12-04</org_study_id>
    <nct_id>NCT01883999</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis</brief_title>
  <official_title>Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized,
      multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE
      Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of the following: Death, Stroke, Myocardial Infarction, Bowel Ischemia,Paraplegia, Respiratory Failure, Renal Failure,Conversion to open surgical repair.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Common Iliac Artery Aneurysms</condition>
  <condition>Aorto-iliac Aneurysms</condition>
  <arm_group>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GORE® EXCLUDER® Iliac Branch Endoprosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® EXCLUDER® Iliac Branch Endoprosthesis</intervention_name>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Common iliac aneurysm with or without concomitant abdominal aortic aneurysm

          2. Adequate native anatomy to receive the EXCLUDER® and Iliac Branch Endoprostheses

          3. An Informed Consent Form signed by Subject or legally authorized representative

          4. Male or infertile female

          5. Able to comply with protocol requirements including following-up

          6. Life expectancy &gt; 2 years

          7. Age &gt; 21 years

          8. Surgical candidate

        Exclusion Criteria:

          1. Mycotic or ruptured aneurysm

          2. Known concomitant thoracic aortic aneurysm which requires intervention

          3. American Society of Anesthesiologists (ASA) Physical Status classification system
             class V (moribund patient not expected to live 24 hours with or without operation)

          4. Renal insufficiency defined or patient undergoing dialysis

          5. New York Heart Association (NYHA) Functional Classification class IV

          6. Dissected, heavily calcified, or heavily thrombosed landing zone(s)

          7. Tortuous or stenotic iliac and/or femoral arteries

          8. Participating in another investigational device or drug study within 1 year of
             treatment

          9. Systemic infection which may increase the risk of endovascular graft infection

         10. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome

         11. Planned concomitant surgical procedure or major surgery within 30 days of treatment
             date

         12. Known history of drug abuse

         13. Known sensitivities or allergies to the device materials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick Pirooz, MHA</last_name>
    <phone>(623) 234-5519</phone>
    <email>npirooz@wlgore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darren Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
